{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-028753","form_type":"8-K","ticker":"FHTX","cik":"0001822462","company_name":"Foghorn Therapeutics Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.355871+00:00","generated_at":"2026-06-22T04:25:35.343201+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Foghorn reports Q3 2022 net loss $25.8M; FDA places FHD-286 AML/MDS trial on full clinical hold","bullets":["Cash $373.5M as of Sep 30, 2022; runway into 2025.","FDA full clinical hold on FHD-286 AML/MDS study due to fatal differentiation syndrome; hold to be resolved.","FHD-286 mUM dose escalation continues; initial data expected H1 2023.","FHD-609 shows BRD9 degradation in synovial sarcoma biopsies; efficacy/safety data expected 2023.","New selective CBP degrader program disclosed; Merck collaboration triggered $5M milestone payment."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-028753","json":"https://secwatch.observer/filing/0001628280-22-028753.json","markdown":"https://secwatch.observer/filing/0001628280-22-028753.md","text":"https://secwatch.observer/filing/0001628280-22-028753.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822462/000162828022028753/0001628280-22-028753-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822462/000162828022028753/fhtx-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T04:25:35.343201+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"302a77c250e46f6b03c601114ae04b1aeee5296f","claim":"Foghorn Therapeutics Inc. reported quarter ended September 30, 2022 results: revenue $6.6 million.","evidence_excerpt":"Collaboration revenues were $6.6 million for the third quarter of 2022 compared to $0.1 million for the third quarter of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822462/000162828022028753/0001628280-22-028753-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended September 30, 2022"},{"label":"Revenue","value":"$6.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}